Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Biocartis Group NV    BCART   BE0974281132

BIOCARTIS GROUP NV

(BCART)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
09/10/2019 09/11/2019 09/12/2019 09/13/2019 09/16/2019 Date
6.64(c) 6.99(c) 6.8(c) 6.57(c) 6.79 Last
595 739 354 834 144 577 324 377 222 367 Volume
-5.68% +5.27% -2.72% -3.38% +3.35% Change
More quotes
Financials (EUR)
Sales 2019 41,7 M
EBIT 2019 -59,4 M
Net income 2019 -67,5 M
Finance 2019 1,60 M
Yield 2019 -
Sales 2020 67,1 M
EBIT 2020 -36,4 M
Net income 2020 -41,7 M
Debt 2020 34,4 M
Yield 2020 -
P/E ratio 2019 -6,01x
P/E ratio 2020 -8,48x
EV / Sales2019 8,84x
EV / Sales2020 6,04x
Capitalization 370 M
More Financials
Company
Biocartis Group specializes in the development of molecular diagnostic systems. Especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group... 
More about the company
Surperformance© ratings of Biocartis Group NV
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOCARTIS GROUP NV
09/05PRESS RELEASE BIOCARTIS NV : Biocartis announces H1 2019 results
AQ
08/29BIOCARTIS GROUP NV : Biocartis announces 2019 half-year results on 5 september 2..
AQ
08/27PRESS RELEASE BIOCARTIS NV : Invitation to the Special Shareholders' Meeting
AQ
08/05BIOCARTIS : Study on Performance Data of Idylla™ NRAS-BRAF Mutation Assay ..
AQ
06/03BIOCARTIS GROUP NV : Biocartis and Kite Sign Agreement for Development of Assays..
AQ
06/01BIOCARTIS GROUP NV : Biocartis and Kite Sign Agreement for Development of Assay..
AQ
05/29BIOCARTIS GROUP NV : Disclosure of transparency notifications
GL
05/17BIOCARTIS GROUP NV : Idylla(TM) MSI Performance Study Selected for Publication a..
AQ
05/17BIOCARTIS GROUP NV : Disclosure of a transparency notification
GL
05/16BIOCARTIS GROUP NV : Idylla(TM) MSI Performance Study Selected for Publication a..
GL
More news
Analyst Recommendations on BIOCARTIS GROUP NV
More recommendations
Sector news : Medical Equipment
01:50aSANOFI : Abbott to Collaborate on Glucose Sensing, Insulin Delivery Data
DJ
09/14Companies ask judge in U.S. opioid trial to recuse himself
RE
09/10BAXTER INTERNATIONAL : to Buy Cheetah Medical for Up to $230 Million
DJ
09/04GLOBAL MARKETS LIVE : Boeing, Bayer, Purdue, KBC…
09/04STRYKER : to Buy Mobius Imaging, Cardan Robotics for Up to $500 Million
DJ
More sector news : Medical Equipment
Chart BIOCARTIS GROUP NV
Duration : Period :
Biocartis Group NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCARTIS GROUP NV
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 13,38  €
Last Close Price 6,57  €
Spread / Highest target 151%
Spread / Average Target 104%
Spread / Lowest Target 52,2%
EPS Revisions
Managers
NameTitle
Herman Verrelst Chief Executive Officer & Executive Director
Christian Reinaudo Chairman
Ewoud Welten Chief Financial Officer
Benoit Devogelaere Chief Technology Officer
Roald Borré Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOCARTIS GROUP NV-33.90%410
ABBOTT LABORATORIES16.51%148 939
MASIMO CORPORATION40.64%8 053
NOVOCURE LTD136.83%7 784
ASAHI INTECC CO., LTD.-42.99%6 191
PENUMBRA INC21.93%5 184